These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 210302)

  • 21. [Post-transfusion hepatitis and its sequelae in the treatment of hemophilia].
    Schimpf K
    Behring Inst Mitt; 1983 Aug; (73):111-7. PubMed ID: 6433878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Blood transfusion and viral diseases. Recent acquisitions concerning viral hepatitis viruses, cytomegaloviruses and Epstein-Barr virus].
    Spanò C
    Minerva Med; 1979 Feb; 70(7):513-20. PubMed ID: 219399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for existence of at least two types of factor-VIII-associated non-B transfusion hepatitis.
    Craske J; Spooner RJ; Vandervelde EM
    Lancet; 1978 Nov; 2(8098):1051-2. PubMed ID: 82066
    [No Abstract]   [Full Text] [Related]  

  • 24. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?
    Mosley JW
    Vox Sang; 1994; 67 Suppl 4():12-5; discussion 24-6. PubMed ID: 7831863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis, type B in haemophiliacs. Relation to the source of clotting factor concentrates.
    Holsteen V; Skinhoj P; Cohn J
    Scand J Haematol; 1977 Mar; 18(3):214-8. PubMed ID: 847395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].
    Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M
    Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278
    [No Abstract]   [Full Text] [Related]  

  • 27. Hemophilia and acquired immune deficiency syndrome.
    Levine PH; Brettler DB; Sullivan JL
    Prog Clin Biol Res; 1985; 182():287-96. PubMed ID: 2994104
    [No Abstract]   [Full Text] [Related]  

  • 28. Human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus antibody. Association with hemophiliacs' immune status and blood component usage.
    Jason J; McDougal JS; Holman RC; Stein SF; Lawrence DN; Nicholson JK; Dixon G; Doxey M; Evatt BL
    JAMA; 1985 Jun; 253(23):3409-15. PubMed ID: 2987559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral serology (hepatitis B virus, cytomegalovirus, Epstein-Barr virus) and abnormal liver function tests in transfused patients with hereditary hemorrhagic diseases.
    Enck RE; Betts RF; Brown MR; Miller G
    Transfusion; 1979; 19(1):32-8. PubMed ID: 219564
    [No Abstract]   [Full Text] [Related]  

  • 30. Non-A, non-B hepatitis and heat-treated factor VIII concentrates.
    Preston FE; Hay CR; Dewar MS; Greaves M; Triger DR
    Lancet; 1985 Jul; 2(8448):213. PubMed ID: 2862396
    [No Abstract]   [Full Text] [Related]  

  • 31. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin.
    Kernoff PB; Lee CA; Karayiannis P; Thomas HC
    Br J Haematol; 1985 Jul; 60(3):469-79. PubMed ID: 3925981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bad blood.
    Coombes R
    BMJ; 2007 Apr; 334(7599):879-80. PubMed ID: 17463458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate.
    Colombo M; Mannucci PM; Carnelli V; Savidge GF; Gazengel C; Schimpf K
    Lancet; 1985 Jul; 2(8445):1-4. PubMed ID: 2861454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cellular immunology status in 5 hemophilic patients with inhibitors subjected to massive therapy with factor VIII concentrate].
    Aznar JA; Jorquera JI; González Molina A; Carbonell F; Trenor A; Sánchez Cuenca JM; de Andrés R
    Sangre (Barc); 1983; 28(5):663-4. PubMed ID: 6420915
    [No Abstract]   [Full Text] [Related]  

  • 35. Aplastic anemia and non-A, non-B hepatitis.
    Zeldis JB; Dienstag JL; Gale RP
    Am J Med; 1983 Jan; 74(1):64-8. PubMed ID: 6295145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs.
    Smid WM; van der Meer J; Halie MR
    Haemostasis; 1995; 25(5):229-36. PubMed ID: 7489961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commercial factor VIII associated hepatitis, 1974-75, in the United Kingdom: a retrospective survey.
    Craske J; Kirk P; Cohen B; Vandervelde EM
    J Hyg (Lond); 1978 Jun; 80(3):327-36. PubMed ID: 649945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequence variability of hepatitis A virus and factor VIII associated hepatitis A infections in hemophilia patients in Europe. An update.
    Robertson BH; Friedberg D; Normann A; Graff J; Flehmig B; Shouval D
    Vox Sang; 1994; 67 Suppl 1():39-45; discussion 46. PubMed ID: 8091736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. The Study Group of the Fondazione dell'Emofilia.
    Mannucci PM; Zanetti AR; Colombo M; Chistolini A; De Biasi R; Musso R; Tamponi G
    Thromb Haemost; 1990 Oct; 64(2):232-4. PubMed ID: 2176748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center.
    Brackmann HH; Oldenburg J; Eis-Hübinger AM; Gerritzen A; Hammerstein U; Hanfland P
    Vox Sang; 1994; 67 Suppl 1():3-7; discussion 8. PubMed ID: 8091733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.